The first-in-class FGFR2b antibody bemarituzumab extends overall survival in patients with advanced gastric cancer, but the benefit shrinks with longer follow-up.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/survival-benefit-novel-gastric-cancer-drug-wanes-2025a1000t0s?src=rss
Author :
Publish date : 2025-10-24 12:59:00
Copyright for syndicated content belongs to the linked Source.
